AFROSCREEN
The AFROSCREEN project aims to establish a genomic surveillance network that helps build laboratory capacity for the diagnosis, detection and surveillance of SARS-CoV-2 variants and other emerging pathogens.
Last updated on 30 March 2026
An international and inter-institutional consortium
Implemented as part of the “Health in Common” initiative in 2021, AFROSCREEN is an international, inter-institutional consortium, demonstrating a voluntary, committed approach to collaborations with major scientific and societal implications. The project has received a share of 10 million euros by the Agence Française de Développement (French Development Agency), coordinated by ANRS | MIE, IRD and Institut Pasteur. It has been implemented by an international network of 25 research centres and laboratories across 13 African countries.
Three main objectives
The three main objectives of the project are as follows:
- Detecting variants of SARS-CoV-2 and other emerging pathogens through building laboratory capacity for sequencing and PCR tests (fitting out facilities, supplying equipment and reagents, online or face-to-face training to staff, and support from network experts).
- Epidemiological investigations
– Tracking trends of SARS-CoV-2 infection to provide warning signal, through sentinel surveillance sites that help collect samples for analysis
– Description of the clinical, biological and epidemiological characteristics of confirmed cases of VOI/VOC of SARS-CoV-2
– Study of the factors involved in household transmission of SARS-CoV-2 variants using perspective surveillance over several weeks. - Helping public health decision-making nationally and internationally by sharing sequencing and epidemiological data.
Depending on partners’ skills, the planned actions will ensure the sustainable development of genomic surveillance capabilities in the country. These actions are provided for the identification of emerging pathogens, for surveys carried out as part of the “One Health” approach (in wildlife, domestic fauna, waste water, etc.) and for research projects.
May 2024: the results of the AFROSCREEN project three years after its launch
Three years after its launch, the AFROSCREEN project has achieved all its objectives by developing an effective genomic surveillance system to tackle epidemics in sub-Saharan Africa. Read about the project’s achievements in the AFROSCREEN press release dated 28 May 2024
See the press release
March 2025: the AFROSCREEN project gains new momentum thanks to additional funding
The AFROSCREEN project reached a further milestone on 24 March 2025, with the award of additional funding from the Ministry for Europe and Foreign Affairs (MEAE).
Under the MEAE’s Fonds Équipe France (FEF), the project is coordinated by a consortium of three French institutions led by ANRS MIE, an autonomous agency of INSERM, and comprising the Research Institute for Development, the Pasteur Institute, and institutions in the project’s partner countries, notably the Pasteur Institute in Dakar and the Centre for Research and Training in Infectious Diseases in Guinea (CERFIG).
This funding aims to consolidate the achievements of the initial project by ensuring the continued operation of the sequencing platforms installed and by strengthening the skills of national staff. It also ensures the continuation of investigations into other emerging and re-emerging zoonotic infectious agents of epidemic potential, such as arboviruses and haemorrhagic fever viruses, the response to which often requires multidisciplinary and multisectoral action. Finally, this funding will enable the continued training of staff from national partners, involving universities in partner countries as well as veterinary laboratories, in line with the ‘One Health’ approach, as part of efforts to consolidate the existing AFROSCREEN network and expand it to include other areas of expertise.
These efforts are aligned with the strategic initiatives of the Africa Centres for Disease Control and Prevention (Africa CDC) and the World Health Organisation (WHO) to establish genomic surveillance networks at national, regional and global levels.
Read the press release